Clinical and healthcare burden of myotonic dystrophy type 1 (DM1) in the United States: a claims-based study
Open Access
- 28 February 2026
- journal article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 641-653
Abstract
No abstract availableFunding Information
- Dyne Therapeutics
This publication has 21 references indexed in Scilit:
- Myotonic Dystrophy (DM) Burden of Disease: A Retrospective Study of Healthcare Costs and Utilization by Individuals With DMMuscle & Nerve, 2025
- Natural history of cardiac involvement in myotonic dystrophy type 1 – Emphasis on the need for lifelong follow-upInternational Journal of Cardiology, 2024
- VP396 More prevalent comorbidities, healthcare costs, and service utilization in male Myotonic Dystrophy (DM) patients and female patientsNeuromuscular Disorders, 2023
- Milestones of progression in myotonic dystrophy type 1 and type 2Muscle & Nerve, 2022
- Disease burden of myotonic dystrophy type 1Journal of Neurology, 2019
- The myotonic dystrophy experience: a North American cross‐sectional studyMuscle & Nerve, 2019
- Development and Validation of a New Scoring System to Predict Survival in Patients With Myotonic Dystrophy Type 1JAMA Neurology, 2018
- Cost of illness for neuromuscular diseases in the United StatesMuscle & Nerve, 2013
- Organ Dysfunction and Muscular Disability in Myotonic Dystrophy Type 1Medicine, 2011
- Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative DataMedical Care, 2005